TABLE OF CONTENTS
1 INTRODUCTION 29
1.1 OBJECTIVES OF THE STUDY 29
1.2 MARKET DEFINITION 29
1.3 OVERVIEW OF MIDDLE EAST-AND AFRICA BLOOD SCREENING MARKET 29
1.4 CURRENCY AND PRICING 30
1.5 LIMITATION 31
1.6 MARKETS COVERED 31
2 MARKET SEGMENTATION 35
2.1 MARKETS COVERED 35
2.2 GEOGRAPHIC SCOPE 36
2.3 YEARS CONSIDERED FOR THE STUDY 37
2.4 CURRENCY AND PRICING 37
2.5 RESEARCH METHODOLOGY 38
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 41
2.7 DBMR MARKET POSITION GRID 42
2.8 THE CATEGORY VS TIME GRID 43
2.9 THE CATEGORY VS TIME GRID 44
2.10 DBMR MARKET CHALLENGE MATRIX 45
2.11 SECONDARY SOURCES 46
2.12 ASSUMPTIONS 46
3 MARKET OVERVIEW 47
3.1 DRIVERS 49
3.1.1 RISE IN THE DEMAND OF BLOOD DONATIONS AND BLOOD DONORS 49
3.1.2 RISING PREVALENCE IN NUMBER OF DISEASES 49
3.1.3 RISING NUMBER OF INITIATIVES BY VARIOUS GOVERNMENTS AND GOVERNMENT ASSOCIATIONS 50
3.2 RESTRAINTS 51
3.2.1 LACK OF USING NAT TECHNLOGY IN EMERGING COUNTRIES 51
3.2.2 HIGH COST OF TECHNOLOGY AND INSTRUMENTS 51
3.2.3 EMERGING ALTERNATIVE TECHNOLOGIES 52
3.3 OPPORTUNITIES 53
3.3.1 INCREASING MICROBIOLOGY SCREENING & MULTIPLEXING 53
3.4 CHALLENGES 54
3.4.1 REDUCTION IN PRICE FOR TECHNOLOGY AND INSTRUMENT 54
4 EXECUTIVE SUMMARY 55
5 PREMIUM INSIGHTS 58
6 MIDDLE EAST-AND AFRICA BLOOD SCREENING MARKET, BY PRODUCTS & SERVICES 60
6.1 OVERVIEW 61
6.2 REAGENTS & KITS 63
6.2.1 ELISA REAGENTS & KITS 65
6.2.1.1 IMMUNOSORBENTS 66
6.2.1.2 CONJUGATES 66
6.2.1.3 SUBSTRATES 66
6.2.1.4 CONTROLS 66
6.2.1.5 SAMPLE DILUENTS AND WASH SOLUTIONS 66
6.2.2 NAT REAGENTS & KITS 66
6.2.2.1 PROBES AND PRIMERS 67
6.2.2.2 ENZYMES AND POLYMERASES 67
6.2.2.3 LABELING AND DETECTION REAGENTS 67
6.2.2.4 STANDARDS AND CONTROLS 67
6.2.2.5 BUFFERS, NUCLEOTIDES AND SOLUTIONS 67
6.3 INSTRUMENTS 68
6.3.1.1 INSTRUMENTS, PRODUCT TYPE 69
6.3.1.1.1 SEMI AUTOMATED 69
6.3.1.1.2 AUTOMATED 69
6.3.1.2 INSTRUMENTS, PURCHASE TYPE 69
6.3.1.2.1 OUTRIGHT PURCHASE 69
6.3.1.2.2 RENTAL 69
6.4 SOFTWARE & SERVICES 70
7 MIDDLE EAST-AND AFRICA BLOOD SCREENING MARKET, BY TECHNOLOGY 71
7.1 OVERVIEW 72
7.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 74
7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY PLATFORM 76
7.2.1.1 COLORIMETRIC IMMUNOASSAY (CI) 76
7.2.1.2 CHEMILUMINESCENCE IMMUNOASSAY (CLIA) 76
7.2.1.3 FLUORESCENCE IMMUNOASSAY (FIA) 76
7.2.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY GENERATIONS 76
7.2.2.1 FIRST-GENERATION ELISA 76
7.2.2.2 SECOND-GENERATION ELISA 76
7.2.2.3 THIRD-GENERATION ELISA 76
7.2.2.4 FOURTH-GENERATION ELISA 76
7.3 RAPID TESTS 77
7.4 NEXT-GENERATION SEQUENCING (NGS) 78
7.5 NUCLEIC ACID TEST 79
7.5.1 REAL-TIME POLYMERASE CHAIN REACTION (PCR) 80
7.5.2 TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA) 80
7.6 WESTERN BLOT ASSAY 81
7.7 OTHERS 82
8 MIDDLE EAST-AND AFRICA BLOOD SCREENING MARKET, BY DISEASE TYPE 83
8.1 OVERVIEW 84
8.2 ONCOLOGY 86
8.3 DIABETES MELLITUS 87
8.4 COLD & FLU 88
8.5 CHOLESTEROL 89
8.6 INFECTIOUS DISEASES 90
8.7 RESPIRATORY DISEASES 91
8.8 HIV/AIDS 92
8.9 OTHERS 93
9 MIDDLE EAST-AND AFRICA BLOOD SCREENING MARKET, BY END USER 94
9.1 OVERVIEW 95
9.2 DIAGNOSTIC CENTERS 97
9.3 BLOOD BANK 98
9.4 HOSPITALS 99
9.5 CLINICS 100
9.6 AMBULATORY SURGICAL CENTERS 101
10 MIDDLE EAST-AND AFRICA BLOOD SCREENING MARKET, BY GEOGRAPHY 102
10.1 MIDDLE EAST & AFRICA 102
10.1.1 SOUTH AFRICA 112
1.1.1 EGYPT
1.1.2 SAUDI ARABIA
1.1.3 UNITED ARAB EMIRATES
1.1.4 ISRAEL
10.1.2 REST OF MIDDLE EAST & AFRICA 119
11 MIDDLE EAST-AND AFRICA BLOOD SCREENING MARKET, COMPANY LANDSCAPE 120
11.1 COMPANY SHARE ANALYSIS; MIDDLE EAST-AND AFRICA 120
12 COMPANY PROFILES 121
12.1 F. HOFFMANN-LA ROCHE LTD 121
12.1.1 COMPANY OVERVIEW 121
12.1.2 REVENUEANALYSIS 121
12.1.3 COMPANY SHARE ANALYSIS 122
12.1.4 PRODUCT PORTFOLIO 122
12.1.5 RECENT DEVELOPMENT 123
12.2 ABBOTT 124
12.2.1 COMPANY OVERVIEW 124
12.2.2 REVENUE ANALYSIS 124
12.2.3 COMPANY SHAREV ANALYSIS 125
12.2.4 PRODUCT PORTFOLIO 125
12.2.5 RECENT DEVELOPMENT 126
12.3 THERMO FISHER SCIENTIFIC INC. 127
12.3.1 COMPANY OVERVIEW 127
12.3.2 REVENUE ANALYSIS 127
12.3.3 COMPANY SHAREV ANALYSIS 128
12.3.4 PRODUCT PORTFOLIO 128
12.3.5 RECENT DEVELOPMENTS 129
12.4 SIEMENS AG 130
12.4.1 COMPANY OVERVIEW 130
12.4.2 REVENUE ANALYSIS 130
12.4.3 COMPANY SHAREV ANALYSIS 131
12.4.4 PRODUCT PORTFOLIO 131
12.4.5 RECENT DEVELOPMENTS 133
12.5 BIO-RAD LABORATORIES, INC. 134
12.5.1 1.3.1COMPANY OVERVIEW 134
12.5.2 REVENUE ANALYSIS 134
12.5.3 COMPANY SHAREV ANALYSIS 135
12.5.4 PRODUCT PORTFOLIO 135
12.5.5 RECENT DEVELOPMENTS 137
12.6 BD 138
12.6.1 COMPANY OVERVIEW 138
12.6.2 REVENUE ANALYSIS 138
12.6.3 PRODUCT PORTFOLIO 139
12.6.4 RECENT DEVELOPMENTS 139
12.7 BECKMAN COULTER, INC. 140
12.7.1 COMPANY OVERVIEW 140
12.7.2 GEOGRAPHICPRESENCE 140
12.7.3 PODUCT PORTFOLIO 141
12.7.4 RECENET DEVELOPEMENTS 142
12.8 BIOM?RIEUX SA 143
12.8.1 COMPANY OVERVIEW 143
12.8.2 REVENUE ANALYSIS 143
12.8.3 PRODUCT PORTFOLIO 144
12.8.4 RECENT DEVELOPMENT 145
12.9 CEPHEID (A SUBSIDIARY OF DANAHER CORPORATION) 146
12.9.1 COMPANY OVERVIEW 146
12.9.2 GEOGRAPHIC PRESENCE 146
12.9.3 PRODUCT PORTFOLIO 147
12.9.4 RECENT DEVELOPMENT 148
12.10 ENZO BIOCHEM INC. 149
12.10.1 COMPANY OVERVIEW 149
12.10.2 REVENUE ANALYSIS 149
12.10.3 PRODUCT PORTFOLIO 150
12.10.4 RECENT DEVELOPMENTS 151
12.11 GRIFOLS INTERNATIONAL, S.A. 152
12.11.1 COMPANY OVERVIEW 152
12.11.2 REVENUE ANALYSIS 152
12.11.3 PRODUCT PORTFOLIO 153
12.11.4 RECENT DEVELOPMENTS 154
12.12 HOLOGIC INC. 155
12.12.1 COMPANY OVERVIEW 155
12.12.2 REVENUE ANALYSIS 155
12.12.3 PRODUCT PORTFOLIO 156
12.12.4 RECENT DEVELOPMENTS 156
12.13 IMMUCOR, INC. 157
12.13.1 COMPANY OVERVIEW 157
12.13.2 GEOGRAPHIC PRESENCE; 157
12.13.3 PRODUCT PORTFOLIO 158
12.13.4 RECENT DEVELOPMENTS 159
12.14 MERIDIAN BIOSCIENCE, INC. 160
12.14.1 COMPANY OVERVIEW 160
12.14.2 REVENUE ANALYSIS 160
12.14.3 PRODUCT PORTFOLIO 161
12.14.4 RECENT DEVELOPMENTS 162
12.15 ORTHO CLINICAL DIAGNOSTICS 163
12.15.1 COMPANY OVERVIEW 163
12.15.2 GEOGRAPHIC PRESENCE 163
12.15.3 PRODUCT PORTFOLIO 164
12.15.4 RECENT DEVELOPMENTS 165
13 RELATED REPORTS 166